Xenon Pharmaceuticals (XENE) Non-Current Debt (2017 - 2019)

Xenon Pharmaceuticals (XENE) has 3 years of Non-Current Debt data on file, last reported at $10.9 million in Q4 2019.

• On a quarterly basis, Non-Current Debt fell 27.47% year-over-year to $10.9 million in Q4 2019; TTM through Dec 2019 was $10.9 million, a 27.47% decrease from a year earlier, with the FY2019 full-year figure at $10.9 million, down 27.47% from the prior year.
• Non-Current Debt for Q4 2019 stood at $10.9 million, down from $11.8 million in the prior quarter.
• Over the last five years, Non-Current Debt for XENE reached as high as $15.1 million in Q1 2019 and fell as low as $5.5 million in Q1 2018.
• Historically, Non-Current Debt has averaged $11.6 million across 3 years, with a median of $11.8 million in 2019.
• On a YoY basis, Non-Current Debt climbed as much as 176.46% in 2019 and fell as far as 27.47% in 2019.
• Year by year, Non-Current Debt stood at $6.1 million in 2017, then surged by 145.97% to $15.0 million in 2018, then dropped by 27.47% to $10.9 million in 2019.
• Per Business Quant data, the three most recent Non-Current Debt figures were $10.9 million in Q4 2019, $11.8 million in Q3 2019, and $13.2 million in Q2 2019.